Tsuyoshi Ito

The #biotech industry is driven by innovative startups and collaborations between academia and industry. #UCBerkeley's Health Innovation Accelerator brings together eight promising #biotechstartups from Taiwan and the US. As these teams tackle global health challenges, from vertigo diagnosis to cancer treatment, they're developing groundbreaking solutions while building cross-cultural partnerships. It's exciting to see how programs like this provide a platform for the mentorship, idea sharing, and progress that could shape the future of the biomedical industry! https://loom.ly/HU6tg5o

1

Kok Song NG and I had breakfast with David Su , founder and managing partner at Matrix Partners China, a venture capitalist, David focuses on software, technology and healthcare investments. He also cofounded San Si Institute, a community of entrepreneurial leaders who are committed to tackle big societal challenges. David who is a graduate of NTU, helps serve on boards of Nanyang Technological University Singapore ,CapitaLand & EDBI Pte Ltd ,has been investing in China for the last two decades , some investments include DiDi , Baidu, Inc. , Focus Group , Heptagon, Bona Films +++++. Was great to chat about geopolitics, Chinese (H share) equity markets, global macro, foreign exchange and about Chinese history. Some of these heavy conversations are best had with roti prata and a cup of coffee ! #venture #vc #venturecapital #geopolitics #macro #globalmacro #policy #healthcare #tech #technology #investments #medtech #biotech #deeptech

107

3件のコメント

Deals ramp up in Asia’s healthcare space with focus on oncology, according to FinanceAsia The new article presents a bird's eye picture of Asia's growth potential in the healthcare sector, particularly emphasizing the surge in investments aimed at next-generation cancer treatments. I linked it in the comments. The detailed account of New Frontier Group's acquisition in Hong Kong, Sunho Biologics' IPO on the Hong Kong stock exchange (HKEX), and AstraZeneca's $1.6 billion investment to build antibody-drug conjugate (ADC) manufacturing facility in Singapore showcases a dynamic and promising future for biotech and pharmaceutical advancements in Asia. Kudos to the author, Andrew Tjaardstra, for highlighting my insights: "These strategic investments and expansions underscore the robust growth potential in Asia's healthcare landscape, particularly in pioneering cancer therapies. It's an exciting time for innovation and development in this critical sector." #asia #venturecapital #healthcare #biotech

29

1件のコメント

Early days but really interesting steps with Car T; the questions of how to accelerate access remains. Current challenges the industry face: Cost: Treatment delivery: Manufacturing complexity. I speak with many leading industry healthcare leaders whose organisations are all working on solutions, finding the right talent that can drive innovation on clinical trial work and manufacturing approaches. Clearly getting all key stakeholders, payers, regulatory agencies, and industry/academia, to collaborate continues to be critical to ensure the potential benefits and impact of this therapy can be truly captured.  

13

📣 I’m proud to announce Springhood Ventures’ investment in NeoPrediX AG, a company committed to revolutionizing maternal and neonatal care through cutting-edge predictive analytics. 💡 Our decision to invest in NeoPrediX is driven by their groundbreaking approach to improving health outcomes during the most critical, formative days of life. By empowering clinicians with real-time, personalized insights, NeoPrediX enables proactive interventions that not only save lives but also elevate the quality of care for mothers and newborns. ✨ NeoPrediX is also tackling the urgent need for greater efficiency and productivity within hospitals. By streamlining processes and equipping healthcare providers with advanced tools, they are helping to reduce costs and improve operational outcomes—a win-win for both patients and healthcare systems. 🌟 📈 NeoPrediX aligns perfectly with Springhood’s mission to improve child health profitably and at scale. This partnership exemplifies the exceptional investment opportunities available in the child health sector. We are excited to collaborate with Thorsten Waloschek and the NeoPrediX team, and we look forward to their continued success in transforming this vital area of healthcare innovation. #SpringhoodVentures #NeoPrediX #investinkids #investinhumanity #mostimportantinvestment

113

11件のコメント

I recently came across an article by Nikkei Asia on menopause in Japan and across Asia, which sheds light on some critical issues and I wanted to share some key insights from it. Japan is currently facing challenges with its declining population and the economic participation of women. A significant barrier is the societal discomfort in discussing menopause openly, making this article particularly impactful. It appears that the Japanese government is beginning to recognize the importance of supporting menopausal women. However, the private sector seems less convinced of the necessity to act, or perhaps they are unsure of how to start addressing this issue. This disparity highlights a crucial area where more awareness and proactive measures are needed to support women and improve their participation in the workforce.

24

4件のコメント

How will the new Trump presidency affect the biotech and pharmaceutical industries? We analyse five impacts that we can see now. https://lnkd.in/gAJuiaxZ

3

Tokyo-Yokohama (Japan) leads as the largest global S&T cluster, followed by Shenzhen-Hong Kong-Guangzhou (China and Hong Kong, China). Beijing (China) moved up one rank from last year to take the third position. In sixth place, San Jose–San Francisco, California is the leading US cluster. China, for the second consecutive year, leads with the most clusters (26) in the top 100. The US follows closely behind with 20 clusters. Clusters located in middle-income economies experienced the strongest S&T growth, with Chinese clusters seeing the steepest increases in S&T output, led by Hefei (+23%) and Zhengzhou (19%).  Cairo (Egypt, with 11% S&T output growth) experienced the highest growth rate amongst other middle-income economy clusters, followed by Chennai (India, +8%) and Istanbul (Turkey, +8%). Conversely, clusters in high-income economies generally grew at a slower pace than those located in middle-income economies, with 37 out of the 63 high-income clusters witnessing negative S&T output growth in 2023. Most North American and European clusters fell in the ranking. In other findings: The Cambridge cluster in the United Kingdom and San Jose–San Francisco in the US are the clusters with the most intensive S&T activity in proportion to population size, followed by Eindhoven (Netherlands), Oxford (UK), and Boston–Cambridge, MA (US). About GII Science and Technology Clusters The GII science and technology clusters are one element in the larger Global Innovation Index (GII), which takes the pulse of the most recent trends in global innovation. The GII science and technology clusters identifies local concentrations of world-leading science and technology (S&T) activity around the globe, using a bottom-up approach. S&T clusters are established through the analysis of patent-filing activity and scientific article publication, documenting the geographical areas around the world with the highest density of inventors and scientific authors. Two innovation metrics are employed in the compilation of the top 100 GII S&T clusters worldwide[1]. The first metric focuses on the location of inventors listed in published patent applications under the WIPO Patent Cooperation Treaty (PCT)[2]. The second metric considers the authors listed on published scientific articles. WIPO locates and ranks science and technology clusters through a geocoding method, mapping addresses and names pulled from documents to a 96% accuracy. https://lnkd.in/gWgSntH7

1

During CHINATRIALS: Global Clinical Development Leaders' Summit in Shanghai, we explored Chinese biopharmas conducting clinical trials in #Japan and rest of Asia Pacific. This is evidenced by the real-life experiences shared by Yiming Du at Haihe, Jin Li at Henlius as well as the support provided by Tetsuomi Takano at T2T Healthcare, and L.E.K. Consulting’s own Yuta Inokuchi.   Highlights of our panel discussion include: * Japan is currently undergoing regulatory reform to enhance the innovative product registration, due to the identification and desire to rectify the “drug loss / drug lag” issue in that market * Adding Japan (and additional markets in Asia Pacific) supports faster product registration in both Japan and the home market of China * While the rules and approaches are different, so there’s an initial learning curve, the Chinese biopharmas also very much appreciate the rule-following Japanese physicians! They have also adapted their approaches via trials and errors – and shared the learnings with the audience   Overall it’s a strong endorsement for Chinese (and I’m sure other nationalities) biopharmas to actively consider Japan as part of their international multi-center trial strategy.   Thank you to the organizers Jon Liong at Lychee and Jialing D. at PharmaDJ for inviting us. Drop me a note if you’d like the L.E.K. presentation which we shared as the foundation of this panel.  

43

4件のコメント

KOREAN STARTUP NEWS. Recent developments from Korean startups have been packed with FDA approvals: • At RSNA 2024, Korean startups like Lunit, VUNO, Coreline Soft, AIRS Medical, and Neurophet showcased cutting-edge AI advancements in medical imaging, including enhanced breast cancer detection, rapid MRI analysis, and comprehensive brain imaging solutions, demonstrating significant breakthroughs in diagnostics and clinical efficiency. • Many Korean healthcare startups, including Team Elysium, 10minds, LEESOL, Apollon, and D&C Biotechnology, have won the CES 2025 Innovation Award for their creative digital healthcare solutions. • NGeneBio has become the first company in Korea to commercialize DNA/RNA-based precision cancer diagnostics, using its ONCOaccuPanel technology to detect gene fusion mutations and enable personalized treatment matching with 33 FDA-approved therapies. • HK inno.N's GERD treatment, K-CAB, has been recommended for approval in India, moving closer to market entry with potential to expand its global impact. To learn more, click the link to the full article in the comments! Source: Korea Biomedical Review, WowTale #KICWashingtonDC #KoreaInnovationCenter #KICDC #KoreanStartups #Startups #LifeScience #Biotech #Medtech #HealthTech #Healthcare #DigitalHealth #Pharma #Pharmaceuticals #MedicalImaging #RSNA #CES2025 #MedicalAI

8

2件のコメント

#藥食同源 FoodMed 2024 -Integrating Food and Chinese Medicine @ Hong Kong Baptist University I am honored to join the conference and assist in moderating and hosting a section of the presentation on behalf of Gobi Partners GBA. Please find the details below: Website: https://foodmed.hk/ Integrating Food and Chinese Medicine: Exploring Science, Technology, and Holistic Approaches for Health In our ongoing quest for optimal health, the importance of food as medicine is gaining attention. As we venture into a transformative world of food and Chinese medicine, what opportunities and challenges lie ahead? What hurdles must be overcome to integrate food as medicine into mainstream health practices fully? How do we address issues of regulations, safety, and efficacy? The inaugural FoodMed Conference invites you to actively engage, contribute, and shape the future of food as medicine by participating in pioneering the scientific validation of food as medicine. The FoodMed conference and exhibition in Hong Kong aim to bring together researchers, innovators, experts, practitioners, and regulators in food and Chinese Medicine (CM) to exchange knowledge, discuss advancements, and explore the future of food and CM in healthcare. The conference will cover various topics, including food innovation and safety, clinical applications, market trends, regulatory considerations, education, and other relevant areas about food as medicine or food-medicine homology. The exhibition will showcase the latest innovations in this field. Event Highlights: - Global Landscape: Gain a comprehensive understanding of the current market dynamics and opportunities for food as medicine. - Innovation and Technology: Explore groundbreaking research shaping the future of food as medicine. - Scientific Validation: Discover how modern technologies enhance the efficacy and scientific evidence of the medicinal properties of food. - Standardization and Globalization: Address challenges and opportunities in garnering local and international acceptance for food as medicine. - Regulatory and Safety Considerations: Understand the regulatory frameworks governing the production and marketing of food as medicine. #Healthcare #VC #Venturecapital #gobi #gba #TCM #wellness #preventivehealthcare

21

1件のコメント

🚀 Researchers at POSTECH, led by Professor Jongmin Kim and Ph.D. candidates Hansol Kang and Dongwon Park, have developed a smart guide RNA capable of multi-signal processing, akin to logic gates in computing. This innovative guide RNA can logically regulate gene expression, enabling precise control of gene networks. Published in Nucleic Acids Research, their work integrates biocomputing with the CRISPR/Cas system, paving the way for advanced gene therapies and personalized treatments. #GeneticEngineering #Biocomputing #CRISPR #POSTECH Read more: https://lnkd.in/e-AF_rQy

3

1件のコメント

Had a great time chatting with Kee Lock Chua , CEO of Vertex Holdings . I learned that Vertex Ventures has six major funds in it’s global network of venture capital funds, each focusing on investments in their respective region and specific sector/industry, the latest being their Japanese Fund. Each independently managed that also raises the majority of its funds from global investors with Vertex Holdings as the anchor investor. Most folks may not know that Vertex Holdings is a wholly-owned subsidiary of Temasek Holdings. Spent time sharing stories about how I remember the NatSteel Holdings Pte Ltd case, when Jackson Tai was at the helm of DBS Bank ; the current #venturecapital environment and #fundraising challenges in the industry for those not distributing; one of the top most important things when investing in ventures- the founder(s) ethics , principles, what drives them, ability to execute ; about Kok Song NG and my recent trip to Japan for Horizons Ventures ‘ techcracker and the developments in the space in Japan; we talked about worms and the sharing by Andrea Choe of Holoclara Inc , an octopus video and neurons on chips by Hon Weng Chong of Cortical Labs and the oh so many possibilities , we talked about the video of a paralysed rat and the work of Andrew Pelling Charles M. Cuerrier of Spiderwort Inc. , ivf ai that led to radiology and pathology diagnostic ai by Dimitry Tran Dr Aengus Tran of Harrison.ai Annalise.ai and their progress globally; we spoke about gene editing and CRISPR; two books I should read by Li Fei -Fei , and Matt Richtel; the importance of continuous curiosity; growing Singapore companies and how to scale ; importance of timing; and about connecting people. Look forward to next time Kee Lock Chua ! #directinvestments #venture #vc #venturecapital #earlystage #entrepreneurship #healthcare #technology #deeptech #founders #principles #investing #learning

241

1件のコメント

On the surface, tech transfer operations (e.g. the process of transferring research and IP into commercialized opportunities) and early-stage startups may seem quite different. But when we at 9point8 Collective dug a little deeper, there was tons of overlap which speaks to the essence of zero-to-one development: 1️⃣ Innovation Focus: both tech transfer and early-stage startups aim to commercialize new technologies or solutions that can address real-world problems or create new opportunities. There is no blueprint to follow. 2️⃣ Intellectual Property: tech transfer ventures usually come with robust IP portfolios, including patents and trade secrets, and early-stage startups often focus on developing and protecting their IP to create a competitive advantage. Leverage IP as an asset is a key part of the strategy. 3️⃣ Market Potential: both tech transfer and early-stage startups target markets with high growth potential. They often aim to disrupt existing industries or create entirely new market segments, so targeting the right markets is essential. 4️⃣ Risk Profile: both types of ventures carry extreme risk and ambiguity due to the uncertainties associated with bringing new technologies or business models to market. With all this overlap, we innovated different versions of our diligence and assessment tool #VentureIQ to focus on tech transfer. Instead of a pitch deck as the raw inputs, we used patent filings instead. We wanted to see if our tech could generate credible insight on how raw technologies can be commercialized. The results have been pretty solid so far. From a single patent filing, we can extract technology readiness levels, target markets, competitors and benchmarks with similar technology, and even sources of public and private funding. From what our design partners have validated for us, these are monumental leaps in the development process -- saving thousands of dollars and weeks of time -- all done with #AI. Know of an interesting #techtransfer use case? Send me a DM so we can chat about it!

11

🌟 Capital for Cures: A New Platform for Healthcare Transformation 🌟 At the beginning of this year, Capital for Cures launched with a bold vision: to mobilize more capital for emerging healthcare companies and solutions. The mission is simple yet urgent—funding healthcare innovation shouldn’t rely solely on the pharmaceutical industry. By expanding our partner network, engaging with pension funds, insurance companies, and other investors, and securing foundational capital, we aim to cultivate the next wave of angel investors, foster collaboration, and provide innovators with the capital they need to thrive. How It Started The idea for Capital for Cures arose from a clear gap in the industry. Early-stage healthcare companies often struggle to secure critical funding, while traditional industry events fail to provide the intimate, action-driven forums needed for impactful collaboration. This inspired the creation of a platform dedicated to fostering meaningful connections among innovators, investors, and policymakers. Recent Milestones Earlier this month, our AI Roundtable in Basel brought together senior leaders from Swiss companies and big data providers involved in foundational AI models, highlighting the urgent need for companies to engage directly with regulators to shape practical AI policies. Additionally, the Capital for Cures event in Frankfurt reinforced the demand for forums like ours. Unlike large-scale conferences, these events showcased the power of action-oriented collaboration to unlock new opportunities. Our Vision for the Future We’re building a fully-fledged platform for transformation: Engaging New Investors: Attracting non-traditional investors, like pension funds and insurance companies, to unlock significant healthcare funding potential. Cultivating Angel Investors: Encouraging successful founders to reinvest in the ecosystem, fueling continuous innovation. Fostering Meaningful Connections: Bridging the gaps left by traditional conferences like Bio-Europe and JP Morgan. Next Steps We are raising $300k USD to scale our vision and mobilize more capital for healthcare innovation. Expanding our partner network is critical to supporting emerging companies and driving impactful change. Join Us Contribute to Our Advisory Board: Bring your expertise or recommend key leaders. Partner with Us: Offer financial or non-monetary support to help scale this transformative initiative. Participate in Upcoming Events: Join our next roundtable to shape the future of AI and healthcare. Together, we can build a brighter future for healthcare by empowering innovators, mobilizing investors, and influencing policies for meaningful change.

21

1件のコメント

KOREAN STARTUP NEWS. Uncover the most recent innovations emerging in Korea's life science startup sector: • 3billion, a Korean biotech firm focused on AI diagnostics for rare genetic diseases, aims to penetrate the U.S. market post-IPO, targeting a $20 trillion global market for genetic testing that could affect 600 million people. They plan to establish its first U.S. branch by 2025. • Matica Biotechnology, based in the U.S. as a subsidiary of CHA Biotech, has signed a letter of intent with U.S.-based KaliVir Immunotherapeutics to provide contract development and manufacturing services for its cancer therapies utilizing the VETTM platform. • Seasun Biomaterials will supply its U-TOP MSI genomic diagnostic products for India's national project on colorectal cancer genetic diagnosis, funded by the Indian Council of Medical Research and aimed at assessing immuno-oncology drug efficacy. • Korean medical AI company VUNO has officially joined Saudi Arabia's Regulatory Healthcare Sandbox initiative, part of the kingdom's broader efforts to diversify its economy and modernize healthcare. For comprehensive details, see the article linked in the comments! Source: Korea Biomedical Review #KICWashingtonDC #KoreaInnovationCenter #KICDC #KoreanStartups #Startups #LifeScience #Biotech #Medtech #Pharma #Pharmaceuticals #Diagnostics #Oncology #Healthcare

7

2件のコメント

A brave, frank and truthful academic - Peking University professor 李玲, in a July 10 interview with Phoenix TV, stated the following - “我们当年做医改方案的时候，8000亿就能实现全民免费医疗。现在9万亿了，你连毛都没摸到。太多人得了不该得的钱” The long-time critic of the rampant and systemic corruption in China’s 医保 system speaks out again. This time on a media platform with state ties and ahead of the Third Plenum. This is a topic I’ve touched on before with posts suggesting China's national health insurance program was on a path of financial insolvency. My comment was based on the data while working on a private enterprise solution to supplement 医保. *the link to the Weibo interview site has been taken down. A new link to the video is in the comment section below. #china #healthcare #reform

10

1件のコメント